---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019674"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:56:04.149282+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CytomX Q1 revenue $23.5M vs $9.0M YoY; cash $204.5M; pipeline advances

## Summary
- Revenue $23.5M in Q1 2023, up from $9.0M Q1 2022, driven by BMS project progress, Astellas milestone, and AbbVie termination revenue recognition.
- Cash, equivalents and investments $204.5M at Mar 31, 2023, versus $193.7M at Dec 31, 2022; includes $35M Moderna upfront and $5M Astellas milestone.
- AbbVie terminated CD71 collaboration; CX-2029 not advanced to additional studies; CytomX evaluating full rights acquisition and next-gen CD71 strategies.
- BMS advanced BMS-986288 (anti-CTLA-4 Probody) from Phase 1 to Phase 2 as lead next-gen CTLA-4 program.
- Marcia Belvin promoted to Chief Scientific Officer; IND filings for CX-2051 and CX-801 targeted for H2 2023.

## SEC filing metadata
- accession: 0000950170-23-019674
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000095017023019674/0000950170-23-019674-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000095017023019674/ctmx-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019674
- JSON: https://secwatch.observer/filing/0000950170-23-019674.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019674.txt

## Key facts
- Earnings Releases
  CytomX Therapeutics, Inc. reported financial results for the three months ended March 31, 2023.
  - Period: the three months ended March 31, 2023
  - Result: reported results
  source text: On May 9, 2023, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501989/000095017023019674/0000950170-23-019674-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.